Новини

01 Oct 2024

One company name, one culture and one way of working!

From 1 October 2024, all Ceres Pharma affiliates changed their local company name to Ceres Pharma.

15 Dec 2023

Ceres Pharma has reached an agreement to acquire Italian Aesculapius Farmaceutici

Ceres Pharma NV, a Belgian based pharmaceutical company, active in Women’s and Family Health, has reached an agreement to acquire 100% of the shares of the Italian pharmaceutical company Aesculapius Farmaceutici  S.r.l.

05 Oct 2023

Ceres Pharma acquires Hungarian VitaPlus

Ceres Pharma NV, a Belgian based pharmaceutical company, active in Women’s and Family Health, has acquired the Hungarian pharmaceutical company VitaPlus Kft, including Innopharm Kft.

08 May 2023

Ceres Pharma acquires Italian Amnol group

Ceres Pharma NV, a Belgian based pharmaceutical company, active in Women and Family Healthcare, has acquired the Italian pharmaceutical group Amnol S.r.l.

06 Oct 2022

Ceres Pharma acquires Belgian Labophar

Ceres Pharma reached an agreement with Dovesco to acquire 100% of the shares of Labophar. Simultaneously Dovesco will re-invest its proceeds in Ceres Pharma.

03 Oct 2022

Ceres Pharma acquires Romanian Dacia Plant

Ceres Pharma, a Belgian based dynamic and fast growing pharmaceutical company, active in Women’s and Family Health, has come to an agreement for the acquisition of the Romanian firm Dacia Plant.

12 Nov 2021

Ceres Pharma acquires GlobiFer Intl.

Belgian based Ceres Pharma, a dynamic and fast growing pharmaceutical company, active in healthcare & well-being, has completed the acquisition of GlobiFer Intl.

12 Jul 2021

Naxicap Partners acquires Ceres Pharma

Naxicap Partners acquires Ceres Pharma NV from Alychlo NV & co-founder Mario Debel who will lead this new phase of growth as CEO and shareholder.

27 May 2021

Ceres Pharma acquires Bulgarian ABOPharma

Belgian based Ceres Pharma, a dynamic and fast-growing pharmaceutical company, active in healthcare & well-being, has completed the acquisition of the Bulgarian firm, ABOPharma. The price of the takeover will not be disclosed.